Platform converts nonhuman antibodies into engineered human antibodies for therapeutic drug applications. KaloBios Pharmaceuticals’ granted Novartis a nonexclusive license its Humaneering™ technology.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KaloBios Pharmaceuticals, Inc. today announced that the company has raised $20 million in the first closing of its Series D venture financing. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results